Harvard Bioscience, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2022 | $46.2M | $76.4M | $5.4M |
| Jun 2022 | $45.8M | $77.5M | $4.3M |
| Sep 2022 | $46.5M | $72.0M | $5.1M |
| Dec 2022 | $43.0M | $72.2M | $4.5M |
| Mar 2023 | $41.1M | $74.3M | $3.8M |
| Jun 2023 | $38.2M | $75.4M | $4.3M |
| Sep 2023 | $35.3M | $74.3M | $5.3M |
| Dec 2023 | $30.7M | $73.1M | $4.3M |
| Mar 2024 | $31.9M | $68.8M | $4.3M |
| Jun 2024 | $32.0M | $67.2M | $4.0M |
| Sep 2024 | $34.3M | $65.3M | $4.6M |
| Dec 2024 | $0 | $63.3M | $4.1M |
| Mar 2025 | $36.4M | $14.8M | $5.5M |
| Jun 2025 | $34.9M | $15.7M | $7.4M |
| Sep 2025 | $34.0M | $14.1M | $6.8M |
| Dec 2025 | $35.9M | $13.7M | $8.6M |
| Mar 2026 | $36.2M | $10.0M | $7.1M |
| Jun 2026 | $36.7M | $7.4M | $6.5M |